Statement of Changes in Beneficial Ownership (4)
March 03 2020 - 05:27PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Karras Nolan E. |
2. Issuer Name and Ticker or Trading
Symbol MERIT MEDICAL SYSTEMS INC [ MMSI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
(Last)
(First)
(Middle)
1600 WEST MERIT PARKWAY |
3. Date of Earliest Transaction (MM/DD/YYYY)
3/2/2020
|
(Street)
SOUTH JORDAN, UT 84095
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock, No Par Value |
|
|
|
|
|
|
|
4000 |
I |
By IRA |
Common Stock, No Par Value |
|
|
|
|
|
|
|
2000 |
I |
Trustee for Revocable Trust |
Common Stock, No Par Value |
3/2/2020 |
|
M |
|
8000 |
A |
$9.95 |
16000 |
D |
|
Common Stock, No Par Value |
3/2/2020 |
|
S |
|
5500 |
D |
$36.69 (1) |
10500 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Non-qualified stock options (right to
buy) |
$9.95 |
3/2/2020 |
|
M |
|
|
8000 |
5/22/2014 (2) |
5/22/2020 |
Common Stock |
0 |
$0 |
0 |
D |
|
Non-qualified stock options (right to
buy) |
$13.99 |
|
|
|
|
|
|
6/11/2015 (3) |
6/11/2021 |
Common Stock |
25000 |
|
25000 |
D |
|
Non-qualified stock options (right to
buy) |
$20.27 |
|
|
|
|
|
|
5/22/2016 (4) |
5/22/2022 |
Common Stock |
25000 |
|
25000 |
D |
|
Non-qualified stock options (right to
buy) |
$18.8 |
|
|
|
|
|
|
5/26/2017 (5) |
5/26/2023 |
Common Stock |
25000 |
|
25000 |
D |
|
Non-qualified stock options (right to
buy) |
$34.4 |
|
|
|
|
|
|
5/24/2018 (6) |
5/24/2024 |
Common Stock |
25000 |
|
25000 |
D |
|
Non-qualified stock options (right to
buy) |
$50.5 |
|
|
|
|
|
|
6/7/2019 (7) |
6/7/2025 |
Common Stock |
25000 |
|
25000 |
D |
|
Non-qualified stock options (right to
buy) |
$52.17 |
|
|
|
|
|
|
5/24/2020 (8) |
5/24/2026 |
Common Stock |
13750 |
|
13750 |
D |
|
Non-qualified stock options (right to
buy) |
$52.17 |
|
|
|
|
|
|
5/31/2020 (9) |
5/31/2026 |
Common Stock |
7500 |
|
7500 |
D |
|
Explanation of
Responses: |
(1) |
The price reported in Column
4 of Table 1 is a weighted average price. These shares were sold in
multiple transactions at prices ranging from $36.48 to $36.98,
inclusive. The Reporting Person undertakes to provide to Merit
Medical Systems, Inc., any security holder of Merit Medical
Systems, Inc., or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this Form 4. |
(2) |
Becomes exercisable in equal
annual installments of 20% commencing 05/22/2014. |
(3) |
Becomes exercisable in equal
annual installments of 20% commencing 06/11/2015. |
(4) |
Becomes exercisable in equal
annual installments of 20% commencing 05/22/2016. |
(5) |
Becomes exercisable in equal
annual installments of 20% commencing 05/26/2017. |
(6) |
Becomes exercisable in equal
annual installments of 20% commencing 05/24/2018. |
(7) |
Becomes exercisable in equal
annual installments of 20% commencing 06/07/2019. |
(8) |
Becomes exercisable in equal
annual installments of 33% commencing 05/24/2020. |
(9) |
Becomes exercisable in equal
annual installments of 33% commencing 05/31/2020. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Karras Nolan E.
1600 WEST MERIT PARKWAY
SOUTH JORDAN, UT 84095 |
X |
|
|
|
Signatures
|
Brian G. Lloyd, Attorney-in-Fact |
|
3/3/2020 |
**Signature of Reporting
Person |
Date |